Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma
暂无分享,去创建一个
Lars Holmgren | Yihai Cao | J. Folkman | M. Moses | M. O'reilly | Yihai Cao | L. Holmgren | Y. Shing | Judah Folkman | Michael S. O'Reilly | Marsha Moses | Catherine Chen | R. Rosenthal | William S. Lane | E. Sage | Yuen Shing | Catherine Chen | Rosalind A. Rosenthal | E.Helene Sage | M. O'Reilly | M. O’Reilly | Evelyne Sage
[1] V. Dixit,et al. Aberrant production of interleukin-8 and thrombospondin-1 by psoriatic keratinocytes mediates angiogenesis. , 1994, The American journal of pathology.
[2] J. Folkman. Angiogenesis and breast cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] A. Ullrich,et al. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant , 1994, Nature.
[4] J. Folkman,et al. Quantitation of angiogenesis and antiangiogenesis in the chick embryo chorioallantoic membrane. , 1994, Microvascular research.
[5] K. Nagata,et al. Microglia‐Derived Elastase Produces a Low‐Molecular‐Weight Plasminogen that Enhances Neurite Outgrowth in Rat Neocortical Explant Cultures , 1993, Journal of neurochemistry.
[6] J. Martial,et al. The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis. , 1993, Endocrinology.
[7] R. Prehn. Two competing influences that may explain concomitant tumor resistance. , 1993, Cancer research.
[8] O. Volpert,et al. Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity , 1993, The Journal of cell biology.
[9] Bing Li,et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo , 1993, Nature.
[10] A. Wyllie,et al. Apoptosis (the 1992 Frank Rose Memorial Lecture). , 1993, British Journal of Cancer.
[11] S. Ben‐Sasson,et al. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation , 1992, The Journal of cell biology.
[12] C. Ponting,et al. Plasminogen: a structural review. , 1992, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[13] L. Weissbach,et al. A plasminogen-related gene is expressed in cancer cells. , 1992, Biochemical and biophysical research communications.
[14] W. Richardson,et al. Cell death and control of cell survival in the oligodendrocyte lineage , 1992, Cell.
[15] A. Ichinose. Multiple members of the plasminogen-apolipoprotein(a) gene family associated with thrombosis. , 1992, Biochemistry.
[16] R. Sasada,et al. Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor. , 1991, Cancer research.
[17] M. Iruela-Arispe,et al. Thrombospondin exerts an antiangiogenic effect on cord formation by endothelial cells in vitro. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[18] E. Prochownik,et al. Antisense-mediated reduction in thrombospondin reverses the malignant phenotype of a human squamous carcinoma. , 1991, The Journal of clinical investigation.
[19] S. Schreiber,et al. Complete amino acid sequence of the FK506 and rapamycin binding protein, FKBP, isolated from calf thymus , 1991, Journal of protein chemistry.
[20] R T Prehn,et al. The inhibition of tumor growth by tumor mass. , 1991, Cancer research.
[21] D. Ingber,et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth , 1990, Nature.
[22] R. Ruggiero,et al. Correlation between seric antitumor activity and concomitant resistance in mice bearing nonimmunogenic tumors. , 1990, Cancer research.
[23] M. L. Le Beau,et al. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[24] R. Auerbach,et al. A hemangioendothelioma-derived cell line: its use as a model for the study of endothelial cell biology. , 1990, Laboratory investigation; a journal of technical methods and pathology.
[25] W. Owen,et al. Neutrophil proteases in plasminogen activation. , 1990, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[26] W. Bursch,et al. Determination of the length of the histological stages of apoptosis in normal liver and in altered hepatic foci of rats. , 1990, Carcinogenesis.
[27] J. Folkman. What is the evidence that tumors are angiogenesis dependent? , 1990, Journal of the National Cancer Institute.
[28] A. Halpern,et al. Model predicting survival in stage I melanoma based on tumor progression. , 1989, Journal of the National Cancer Institute.
[29] W. Owen,et al. An elastase-dependent pathway of plasminogen activation. , 1989, Biochemistry.
[30] N Gunduz,et al. Presence of a growth-stimulating factor in serum following primary tumor removal in mice. , 1989, Cancer research.
[31] Peter J. Polverini,et al. Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene , 1989, Cell.
[32] R. Ruggiero,et al. Role of concomitant resistance in the development of murine lung metastases , 1988, International journal of cancer.
[33] J. Williams,et al. Heparin-binding fragments of fibronectin are potent inhibitors of endothelial cell growth. , 1985, The American journal of pathology.
[34] W. Mangel,et al. Quantitative characterization of the binding of plasminogen to intact fibrin clots, lysine-sepharose, and fibrin cleaved by plasmin. , 1985, Biochemistry.
[35] R. Ruggiero,et al. "Concomitant immunity" in murine tumours of non-detectable immunogenicity. , 1985, British Journal of Cancer.
[36] N Gunduz,et al. Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases. , 1983, Cancer research.
[37] E. Gorelik. Concomitant tumor immunity and the resistance to a second tumor challenge. , 1983, Advances in cancer research.
[38] E. Gorelik. Resistance of tumor-bearing mice to a second tumor challenge. , 1983, Cancer research.
[39] Michael Feldman,et al. On the mechanism of tumor ‘concomitant immunity’ , 1981, International journal of cancer.
[40] S. Segal,et al. Control of lung metastasis progression in mice: role of growth kinetics of 3LL Lewis lung carcinoma and host immune reactivity. , 1980, Journal of the National Cancer Institute.
[41] P. Lerch,et al. Localization of individual lysine-binding regions in human plasminogen and investigations on their complex-forming properties. , 1980, European journal of biochemistry.
[42] Mayo,et al. Accelerated growth of testicular cancer after cytoreductive surgery , 1980 .
[43] J. Folkman,et al. Long-term culture of capillary endothelial cells. , 1979, Proceedings of the National Academy of Sciences of the United States of America.
[44] N Gunduz,et al. Effect of surgical removal on the growth and kinetics of residual tumor. , 1979, Cancer research.
[45] R. Auerbach,et al. Angiogenesis in the mouse cornea. , 1979, Science.
[46] Michael Feldman,et al. GROWTH OF A LOCAL TUMOR EXERTS A SPECIFIC INHIBITORY EFFECT ON PROGRESSION OF LUNG METASTASES , 1978, International journal of cancer.
[47] E. Schöpf,et al. Inhibition of DNA synthesis by a factor from ascites tumor cells. , 1977, European journal of cancer.
[48] C. Elleman,et al. Suppressive factors in ascitic fluids and sera of mice bearing ascites tumors. , 1977, Journal of the National Cancer Institute.
[49] L Simpson-Herren,et al. Effects of surgery on the cell kinetics of residual tumor. , 1976, Cancer treatment reports.
[50] J. Yuhas,et al. Inhibition of subcutaneously growing line 1 carcinomas due to metastatic spread. , 1974, Cancer research.
[51] H. Withers,et al. Immunological resistance to pulmonary metastases in C3Hf-Bu mice bearing syngeneic fibrosarcoma of different sizes. , 1974, Cancer research.
[52] W. Dewys. Studies correlating the growth rate of a tumor and its metastases and providing evidence for tumor-related systemic growth-retarding factors. , 1972, Cancer research.
[53] J. Folkman. Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.
[54] P. Bichel. Autoregulation of ascites tumour growth by inhibition of the G-1 and the G-2 phase. , 1971, European journal of cancer.
[55] D. Deutsch,et al. Plasminogen: Purification from Human Plasma by Affinity Chromatography , 1970, Science.
[56] D. Rounds. A growth-modifying factor from cell lines of human malignant origin. , 1970, Cancer research.
[57] F. Rapp,et al. Concomitant immunity in hamsters bearing dmba‐induced tumor transplants , 1969, International journal of cancer.
[58] V. Kinzel,et al. Chalones and Cancer: Melanoma Regression induced by “Chalone”: a New Tumour Inhibiting Principle acting in vivo , 1968, Nature.
[59] R. Gershon,et al. On Concomitant Immunity in Tumour-bearing Hamsters , 1967, Nature.
[60] Howard Jm. STUDIES OF AUTOTRANSPLANTATION OF INCURABLE CANCER. , 1963 .
[61] G. Moore,et al. Heterologous, homologous, and autologous transplantation of human tumors , 1963, Cancer.
[62] C. Southam,et al. Quantitative studies of autotransplantation of human cancer. Preliminary report , 1961 .
[63] C. Southam,et al. QUANTITATIVE STUDIES OF AUTOTRANSPLANTATION OF HUMAN CANCER , 1961 .
[64] H. Greene,et al. The inhibitory influence of a transplanted hamster lymphoma on metastasis. , 1960, Cancer research.
[65] W. Schatten. An experimental study of postoperative tumor metastases. I. Growth of pulmonary metastases following total removal of primary leg tumor , 1958, Cancer.
[66] Tyzzer Ee,et al. Factors in the Production and Growth of tumor Metastases. , 1913 .
[67] E. F. Bashford,et al. The Natural and Induced Resistance of Mice to the Growth of Cancer , 1907 .